Table 5– Number of anti-tuberculosis (TB) drugs prescribed and duration of therapy by extensively drug-resistant (XDR)-TB patient group
XDR aloneXDR+2sliXDR+sliG4XDR+sliG4EZ
Subjects301684842
Number of prescribed drugs
 Initial phase5.2±1.15.3±1.15.0±0.84.9±0.9
 Continuation phase4.1±1.04.5±0.73.7±0.83.7±0.8
Duration of therapy# months
 Initial phase9.8±6.512.0±7.56.3±8.26.8±8.7
 Total therapy22.4±17.818.1±12.316.5±5.716.5±6.2
  • Data are presented as n or mean±sd. This analysis excludes those who died or defaulted, as therapy was truncated by these events. XDR alone: resistance to isoniazid and rifampicin, plus any fluoroquinolone and any second-line injectable drug (sli); XDR+2sli: XDR-TB, plus resistance to both an aminoglycoside injectable (kanamycin/amikacin) and to capreomycin; XDR+sliG4: XDR-TB, plus resistance to all second-line TB drugs tested, with, as a minimum, resistance to kanamycin and to at least one group 4 drug (G4); XDR+sliG4EZ: XDR-TB, plus resistance to all first- and second-line TB drugs tested, with, as a minimum, resistance to kanamycin, one group 4 drug and either pyrazinamide (Z) and/or ethambutol (E). #: duration of treatment estimated only for those with treatment success or failure/relapse.